Compare · NRC vs SRNE
NRC vs SRNE
Side-by-side comparison of NRC Health (NRC) and Sorrento Therapeutics Inc. (SRNE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NRC and SRNE operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- NRC carries a market cap of $563.6M.
- NRC has hit the wire 6 times in the past 4 weeks while SRNE has been quiet.
- SRNE has more recent analyst coverage (2 ratings vs 1 for NRC).
- Company
- NRC Health
- Sorrento Therapeutics Inc.
- Price
- -
- -
- Market cap
- $563.6M
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 6
- 0
- Recent ratings
- 1
- 2
NRC Health
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
Sorrento Therapeutics Inc.
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patients with melanoma; and Karolinska Institutet. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Latest NRC
- EVP & Chief Operating Officer Hrdy Helen exercised 12,619 shares at a strike of $18.80 and covered exercise/tax liability with 10,491 shares, increasing direct ownership by 2% to 142,646 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by NRC Health
- SEC Form 10-Q filed by NRC Health
- SEC Form 8-K filed by NRC Health
- NRC Health Announces Third Quarter 2026 Results
- NRC Health Launches nQuire Pro, Extending the Reach of Patient-Experience Teams
- SEC Form 8-K filed by NRC Health
- New NRC Health Research Reveals What Sets High-Performing Health Systems Apart: Turning Patient Feedback Into Action
- The Governance Institute Blue Ribbon Committee Reframes Hospital and Health System Board Assessment with Four Considerations for Stronger Governance
- KLAS First Look: NRC Health Rounding Earns 91.6 Overall Performance Score
Latest SRNE
- Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025
- Sorrento Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Regulation FD Disclosure, Other Events
- Sorrento Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Sorrento Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Sorrento Therapeutics Inc.
- Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits